1-2 of 2
Martha Lacy, M.D.
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase II Trial of Myeloma Induction Therapy with Cyclophosphamide, Bortezomib, and Dexamethasone (Cybor-D): Improved Response over Historical Lenalidomide-Dexamethasone Controls.

Craig B. Reeder, MD, Donna E. Reece, M.D., Rafael Fonseca, M.D., P. Leif Bergsagel, M.D., Joseph Hentz, MSc., Nicholas A. Pirooz, BSc., Jacy E. Boesiger, RN., Jesus G. Pisa, M.D., Vishal Kukreti, M.D., Christine Chen, M.D., Suzanne Trudel, M.D., Joseph R. Mikhael, M.D., Martha Lacy, M.D., S. Vincent Rajkumar, M.D., A. Keith Stewart, M.D.
Journal: Blood
Blood (2007) 110 (11): 3601.
https://doi.org/10.1182/blood.V110.11.3601.3601
Published: 2007
Journal Articles

Cardiac Biomarkers Predict for Ability To Tolerate and Complete Therapy with Lenalidomide ± Dexamathosone in AL Amyloidosis.

Angela Dispenzieri, MD, Martha Lacy, M.D., Steven Zeldenrust, M.D., Ph.D., Suzanne R. Hayman, M.D., Shaji Kumar, M.D., Susan M. Geyer, Ph.D., John A. Lust, M.D., Ph.D., Jacob B. Allred, M.S., Thomas E. Witzig, M.D, S. Vincent Rajkumar, M.D., Philip R. Greipp, M.D., Stephen J. Russell, M.D., Ph.D., Brian Kabat, Morie Abraham Gertz, M.D.
Journal: Blood
Blood (2006) 108 (11): 130.
https://doi.org/10.1182/blood.V108.11.130.130
Published: 2006